Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. (2019)

First Author: Sale MJ
Attributed to:  How does ERK1/2-dependent phosphorylation target BimEL to the proteasome? funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-019-12409-w

PubMed Identifier: 31727888

Publication URI: http://europepmc.org/abstract/MED/31727888

Type: Journal Article/Review

Volume: 10

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723